ArticleNPJ breast cancer2025
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Randomized Multicenter Comparative Trial Of 5 Years Adjuvant Exemestane Treatment Versus 5 Years Adjuvant Tamoxifen Treatment In Postmenopausal Women With Early Breast Cancer
Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer
Who cites it
1 citing paper in PubMed.
- Breast Cancer Index and Recommendations for Extended Endocrine Therapy.JAMA network open · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Breast Cancer Index (BCI) was previously shown to identify ~20% of postmenopausal patients with early stage, hormone receptor positive (HR+), node negative (N0) breast cancer with minimal (<5%) risk of 10-year distant recurrence (DR) even without receiving adjuvant endocrine therapy (ET). This prospective-retrospective study further validated the BCI minimal risk classification in postmenopausal patients with early-stage, HR + HER2- N0 breast cancer from the Netherlands Cancer Registry (NCR) and the Tamoxifen and Exemestane Adjuvant Multinational (TEAM, NCT00279448, NCT00032136) randomized trial who received 5 years of primary adjuvant ET. BCI classified approximately 15% of patients as minimal risk. In the NCR cohort (n = 1264 out of 15,053 HR+ patients in the registry), risks of DR in the minimal, low, intermediate, and high groups were 4.8%, 3.3%, 8.0%, and 12.4%, respectively (P < 0.001). In the TEAM cohort (n = 978 out of 3544 in the BCI study), DR risks were 3.8%, 8.3%, 12.6% and 22.7% (P < 0.001). In multivariate analyses, BCI risk scores provided independent information over standard prognostic factors (P < 0.001). This study confirmed the ability of the adjusted BCI model to identify postmenopausal women with HR + HER2- N0 breast cancer who are at minimal risk of DR and may consider de-escalating adjuvant ET.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.